SEC receives amended S-1 for 21Shares Injective ETF
The SEC has received an amended registration statement for the 21Shares Injective ETF, updating an original S-1 from October 2025 and moving the proposed fund closer to potential Nasdaq listing under ticker TINJ. The fund would passively track INJ token performance through the FTSE Injective Index and may stake a portion of holdings at the manager's discretion. The preliminary prospectus shows shares have not yet traded and contains no financial statements, while custody arrangements remain unfinalized. With INJ circulating supply near 92.8 million and market capitalization about $488 million, approval could give regulated access and materially affect token float.
Filing would give regulated INJ access with discretionary staking
Context
21Shares filed an original S-1 in October 2025 and now sent an amended S-1/A. The SEC review is ongoing and custody details are not yet finalized. If approved, the ETF would list on Nasdaq and may influence INJ supply dynamics.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Historical ParallelLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked